No—Continue Both Insulin and Dextrose-Containing Fluids Simultaneously
In DKA, you should never hold the insulin infusion once started; instead, when glucose falls below 200-250 mg/dL, add dextrose-containing IV fluids (D5NS or D10NS) while maintaining the insulin infusion at the same rate until the ketoacidosis resolves. 1
The Critical Principle: Insulin Clears Ketones, Not Just Glucose
The fundamental error in DKA management is stopping insulin when glucose normalizes. Insulin is required to shut off ketone production and clear the acidosis—this process continues even after glucose correction. The 2025 ADA Standards explicitly state: "Keep glucose between 150 and 200 mg/dL until resolution" for DKA, achieved by adding dextrose to fluids, not by stopping insulin 1.
The Two-Bag Strategy
When blood glucose drops to 200-250 mg/dL:
- Continue the insulin infusion unchanged (typically 0.1 units/kg/hour or fixed-rate protocol)
- Add dextrose-containing fluids (D5NS initially, can increase to D10NS if needed)
- Run both simultaneously: crystalloid for hydration + dextrose solution to maintain glucose 150-200 mg/dL
- Titrate the dextrose infusion rate to keep glucose in target range while insulin continues clearing ketones
Recent evidence shows the two-bag method (simultaneous crystalloid + dextrose bags) reduces time to DKA resolution, decreases hypoglycemia risk (3-10% vs 30% with traditional one-bag switching), and shortens hospital stay 2, 3.
Resolution Criteria—When to Actually Stop Insulin
Continue IV insulin until ALL of the following are met 1:
- Anion gap normalized (typically <12 mEq/L)
- Venous pH ≥7.3
- Bicarbonate ≥18 mEq/L
- Patient able to eat and drink
Common pitfall: Stopping insulin when glucose normalizes but before anion gap closes leads to rebound DKA in up to 40% of cases 4. Implementation of protocols preventing premature insulin discontinuation reduced rebound DKA from 40% to 8% 4.
Transition to Subcutaneous Insulin
Once DKA resolves:
- Give subcutaneous basal + bolus insulin
- Continue IV insulin for 1-2 hours after subcutaneous dose to ensure adequate overlap 1, 5, 6
- Then discontinue IV infusion
Insufficient overlap timing is a major cause of DKA recurrence 5.
Monitoring During Dual Therapy
- Check glucose every 1-2 hours
- Check electrolytes, pH, anion gap every 2-4 hours 1
- Adjust dextrose concentration/rate to maintain glucose 150-200 mg/dL
- Never adjust insulin rate based on glucose alone—adjust based on ketone clearance and acidosis resolution
Special Consideration: Euglycemic DKA
In euglycemic DKA (glucose <200 mg/dL at presentation, often SGLT2i-related), start dextrose-containing fluids immediately alongside insulin from the beginning of treatment 7. Use fixed-rate insulin infusion with dextrose titration rather than glucose-based insulin adjustment 7.
The evidence is unequivocal: holding insulin to prevent hypoglycemia in DKA is dangerous and leads to treatment failure. The correct approach is adding dextrose to maintain safe glucose levels while continuing insulin to resolve the metabolic crisis.